PMC:7195088 / 31064-31583 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T34","span":{"begin":92,"end":100},"obj":"Body_part"},{"id":"T35","span":{"begin":155,"end":157},"obj":"Body_part"},{"id":"T36","span":{"begin":171,"end":173},"obj":"Body_part"},{"id":"T37","span":{"begin":271,"end":279},"obj":"Body_part"}],"attributes":[{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A37","pred":"fma_id","subj":"T37","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":". Primary endpoint: ICU admission (follow-up 29 days)\nTocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day "}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T24","span":{"begin":506,"end":511},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":". Primary endpoint: ICU admission (follow-up 29 days)\nTocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T161","span":{"begin":321,"end":329},"obj":"Disease"},{"id":"T162","span":{"begin":412,"end":420},"obj":"Disease"}],"attributes":[{"id":"A161","pred":"mondo_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A162","pred":"mondo_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":". Primary endpoint: ICU admission (follow-up 29 days)\nTocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T172","span":{"begin":66,"end":75},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T173","span":{"begin":128,"end":136},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T174","span":{"begin":293,"end":296},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T175","span":{"begin":427,"end":432},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":". Primary endpoint: ICU admission (follow-up 29 days)\nTocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T418","span":{"begin":102,"end":113},"obj":"Chemical"},{"id":"T419","span":{"begin":155,"end":157},"obj":"Chemical"},{"id":"T421","span":{"begin":171,"end":173},"obj":"Chemical"},{"id":"T423","span":{"begin":362,"end":373},"obj":"Chemical"},{"id":"T424","span":{"begin":427,"end":432},"obj":"Chemical"}],"attributes":[{"id":"A418","pred":"chebi_id","subj":"T418","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A419","pred":"chebi_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A420","pred":"chebi_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A421","pred":"chebi_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A422","pred":"chebi_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A423","pred":"chebi_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A424","pred":"chebi_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":". Primary endpoint: ICU admission (follow-up 29 days)\nTocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day "}

{"project":"LitCovid-sentences","denotations":[{"id":"T243","span":{"begin":2,"end":53},"obj":"Sentence"},{"id":"T244","span":{"begin":54,"end":170},"obj":"Sentence"},{"id":"T245","span":{"begin":171,"end":421},"obj":"Sentence"},{"id":"T246","span":{"begin":422,"end":471},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":". Primary endpoint: ICU admission (follow-up 29 days)\nTocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day "}